ERBB2 and cancer: To test the reliability and robustness of the assay, a set of reciprocal experiments were carried out, in which the EVs from three different types of cancer were immobilised using antibodies against two EV markers, that is, CD9 and CD81, whilst the aptamer against HER2 was used as the detection probe for cancer biomarker.